Health Condition 1: L700- Acne vulgaris
Conditions
Interventions
Intervention1: Fixed-dose gel containing topical Adapalene + Benzoyl Peroxide + Clindamycin: Fixed combination topical gel containing Adapalene 0.15 percent, Benzoyl Peroxide 3.1 percent and Clindamyc
Sponsors
AIIMS Jammu
Eligibility
Inclusion criteria
Inclusion criteria: Male and female patients aged 12-45 years. Clinical diagnosis of mild (few inflammatory lesions (papules/pustules) only; no nodulocystic lesions; IGA score 2) to moderate (multiple inflammatory lesions present; many papules/pustules; there may or may not be a few nodulocystic lesions, IGA score 3) acne vulgaris. Willingness to avoid use of other acne medications during the study. Written informed consent obtained.
Exclusion criteria
Exclusion criteria: Severe acne (Inflammatory lesions are more apparent, many papules,pustules; there may or may not be a few nodulocystic lesions; IGA 4 or more. Presence of nodulocystic, conglobate, or acne fulminans variants. Clinical or biochemical features suggestive of hormonal acne, such as polycystic ovarian syndrome (PCOS) or hyperandrogenism. Use of topical or systemic retinoids, corticosteroids, antibiotics, or hormonal therapy within the previous 4 weeks. Pregnant or lactating women. Known hypersensitivity to study medications. Presence of systemic illness, immunocompromised state, or chronic dermatologic conditions affecting the face. History of drug induced acne or use of comedogenic cosmetic products.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in acne severity measured by Investigator Global Assessment scoreTimepoint: Baseline, week 4, week 8, week 12, week 16, week 20, week 24, and week 28 | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction in inflammatory and non inflammatory lesion countsTimepoint: Baseline, week 4, week 8, week 12, week 16, week 20, week 24, and week 28 | — |
Countries
India
Contacts
Public ContactNasna V
AIIMS Jammu
Outcome results
None listed